To receive all of Ikonisys’ financial information in real time, send a request by email to [email protected]. Your registration will be immediate.
• Successful IPO in July 2021 on Euronext Growth Paris
• Successful installation of the Ikoniscope20 at TomaLab, one of the largest genetic laboratories in Italy (post-closing)
• The preliminary results of the Ikoniscope20 obtained in collaboration with the Faculty of Medicine of the University of Connecticut (Neag Cancer Center of UConn) in the detection of rare cells are superior to the analysis standards in immuno-oncology (post-closing )
• Acceleration of sales and marketing strategy with the recruitment of two Sales Directors for the United States (September 2021) then the European market (post-closing, February 2022)